Talking Medicines joins 2026 UK AI Index

Tern plc

Talking Medicines has been named in the 2026 UK AI Index, placing it among the top 1,000 AI companies in the country.

The company’s core offering focuses on converting unstructured healthcare dialogue into structured, actionable intelligence for pharmaceutical clients. By applying natural language processing and machine learning to patient and healthcare professional conversations, Talking Medicines helps pharma teams improve how they position medicines, understand brand performance and engage with clinicians. This use of real-world voice data offers a practical solution to the ongoing challenge of making sense of fragmented health communications.

Recognition by the UK AI Index gives Talking Medicines a stronger position within a national network of AI companies that are attracting attention from both investors and policymakers. The index is supported by government and industry groups aiming to map out leadership in artificial intelligence across sectors such as health, finance and energy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search